News | December 30, 2023
Venus Remedies secures marketing approval from Israel, Colombia for two oncology drugs
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Fischer Chemic will make an entry into the growing market of diagnostic imaging industry with innovative and disruptive technologies
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
_256_384.jpg)
GenWorks Health Introduces Braster Pro for breast screening & EVA for cervical screening in rural areas & communities
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
Medica Superspecialty Hospital becomes the first private hospital in Eastern India to collaborate with UNICEF for breastfeeding workshop
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection
Subscribe To Our Newsletter & Stay Updated
